AXL and glioblastoma: BGB324, a novel small molecule inhibitor of AXL, alone prolonged the survival of mice bearing human mesenchymal GBM cells, and combinatorial therapy with BGB324 and nivolumab prolonged the survival of mice bearing GBM tumors and increased cell death 103.